What is Becker muscular dystrophy?
Becker muscular dystrophy (BMD) is a rare genetic disorder that causes progressive muscle weakness and wasting, primarily affecting boys and men. It is caused by mutations in the dystrophin gene that result in reduced or abnormal dystrophin protein production, leading to muscle fiber damage over time. BMD affects approximately 1 in 18,000 male births worldwide, making it less common than its more severe counterpart, Duchenne muscular dystrophy. Unlike other forms of muscular dystrophy, BMD typically has a later onset and slower progression, allowing many individuals to maintain the ability to walk well into adulthood.
Key statistics
| Prevalence | ~1 in 18,000 male births |
| Age of onset | Usually 5-15 years, can be later |
| Inheritance pattern | X-linked recessive |
| Carrier frequency | ~1 in 9,000 females |
Symptoms
Muscle weakness (especially in hips and shoulders), difficulty climbing stairs, frequent falls, enlarged calf muscles, fatigue, heart problems, breathing difficulties.
The symptoms of BMD typically develop gradually during childhood or adolescence. Early signs include difficulty running, jumping, or climbing stairs, along with frequent falls and trouble rising from the ground. Unlike Duchenne muscular dystrophy, children with BMD often maintain normal early motor development milestones.
The weakness typically begins in the proximal muscles—those closest to the center of the body, particularly affecting the hips, pelvis, thighs, and shoulders. Many individuals develop enlarged calf muscles (pseudohypertrophy) due to fat and connective tissue replacing normal muscle fibers. As the condition progresses, walking may become more difficult, though most people with BMD retain the ability to walk much longer than those with Duchenne muscular dystrophy.
Cardiac complications are common and serious, with dilated cardiomyopathy developing in approximately 70-80% of individuals with BMD. This heart muscle weakness can occur even in those with relatively mild skeletal muscle symptoms. Respiratory muscle weakness typically develops later in the disease course and may require breathing support during sleep or illness.
Causes and risk factors
BMD is caused by mutations in the DMD gene located on the X chromosome, which provides instructions for making dystrophin protein. Dystrophin is essential for maintaining the structural integrity of muscle fibers by connecting the internal framework of muscle fibers to the surrounding membrane.
The inheritance pattern is X-linked recessive, meaning the condition primarily affects males who inherit one mutated copy of the gene from their mothers. Females who carry one mutated copy are typically unaffected carriers, though some may experience mild symptoms such as muscle cramps or cardiomyopathy.
In BMD, mutations typically allow some functional dystrophin protein to be produced, though it may be reduced in quantity or altered in structure. This contrasts with Duchenne muscular dystrophy, where dystrophin production is severely impaired or absent entirely.
Approximately two-thirds of cases are inherited from carrier mothers, while one-third result from new spontaneous mutations. Advanced paternal age may slightly increase the risk of new mutations, though this association is not as strong as in some other genetic conditions.
Prevention
As a genetic condition, BMD cannot be prevented through lifestyle modifications or environmental changes. However, genetic counseling and testing play crucial roles in family planning decisions for at-risk families.
Carrier testing can identify women who carry a mutation in the DMD gene, allowing them to understand their risk of having affected children. Prenatal testing through chorionic villus sampling or amniocentesis can detect BMD in male fetuses when a family mutation is known.
Preimplantation genetic diagnosis (PGD) is available for families with known mutations, allowing selection of unaffected embryos during in vitro fertilization. Genetic counseling is strongly recommended for families affected by BMD to understand inheritance patterns, testing options, and reproductive choices.
Complications
Without proper management, BMD can lead to significant complications affecting multiple body systems. Progressive muscle weakness may eventually result in loss of ambulation, typically occurring later than in Duchenne muscular dystrophy, often in the third or fourth decade of life.
Dilated cardiomyopathy represents the most serious complication, potentially leading to heart failure, arrhythmias, and sudden cardiac death. Cardiac complications can occur independently of skeletal muscle severity and may be the presenting feature in some individuals.
Respiratory complications develop as the diaphragm and other breathing muscles weaken, increasing susceptibility to pneumonia and respiratory infections. Sleep-disordered breathing and eventual respiratory failure may occur in advanced cases.
Scoliosis and joint contractures can develop due to muscle weakness and imbalance, potentially affecting mobility and comfort. Bone health may be compromised due to reduced mobility and potential steroid use, increasing fracture risk.
Diagnosis
The diagnostic journey for BMD often begins with recognition of muscle weakness, elevated muscle enzymes, or family history. Initial blood tests typically reveal markedly elevated creatine kinase (CK) levels, often 10-100 times normal values, indicating ongoing muscle damage.
Genetic testing for mutations in the DMD gene has become the primary diagnostic method, capable of identifying the specific mutation in approximately 95% of cases. Multiplex ligation-dependent probe amplification (MLPA) can detect large deletions or duplications, while DNA sequencing identifies smaller mutations.
Muscle biopsy may be performed when genetic testing is inconclusive, allowing examination of dystrophin protein levels and distribution through immunohistochemistry and Western blot analysis. In BMD, dystrophin is typically present but reduced in quantity or altered in size.
Electromyography (EMG) may show myopathic changes, though it’s not specific for BMD. Cardiac evaluation including echocardiogram and electrocardiogram is essential given the high frequency of cardiac involvement. Pulmonary function tests assess respiratory muscle strength and lung capacity.
Treatment
Currently, there is no cure for BMD, but comprehensive management can significantly improve quality of life and slow progression. Prednisolone and other corticosteroids may help preserve muscle strength and function, though their use in BMD is less established than in Duchenne muscular dystrophy.
Cardiac management is crucial and may include ACE inhibitors, beta-blockers, or other heart medications to treat cardiomyopathy. Some individuals may require devices such as pacemakers or implantable cardioverter-defibrillators for serious heart rhythm problems.
Physical therapy and occupational therapy help maintain mobility, prevent contractures, and adapt to changing abilities. Respiratory care may include airway clearance techniques, assisted ventilation during sleep, or mechanical ventilation in advanced cases.
Orthopedic interventions such as surgery for scoliosis or tendon releases for contractures may be beneficial in selected cases. Assistive devices including braces, wheelchairs, and home modifications can help maintain independence and safety.
Several investigational treatments are in development, including gene therapy approaches, exon-skipping strategies, and utrophin upregulation therapies that have shown promise in clinical trials.
Prognosis
The prognosis for BMD is generally more favorable than for Duchenne muscular dystrophy, with significant variability between individuals. Many people with BMD maintain the ability to walk into their 40s, 50s, or beyond, depending on the specific genetic mutation and individual factors.
Life expectancy is often reduced primarily due to cardiac and respiratory complications rather than skeletal muscle weakness alone. With proper cardiac monitoring and treatment, many individuals can live productive lives well into middle age and beyond.
The rate of progression varies considerably, with some individuals experiencing rapid decline while others maintain functional abilities for decades. Generally, later age of onset correlates with slower progression and better long-term outcomes.
Quality of life can remain good with appropriate support and management, allowing many individuals to pursue education, careers, relationships, and family life. Early intervention and comprehensive care significantly improve outcomes and functional independence.
Quality of life
Living with BMD requires adaptations but doesn’t preclude a fulfilling life. Regular, moderate exercise as tolerated can help maintain muscle strength and cardiovascular health, though overexertion should be avoided. Swimming and water-based exercises are often well-tolerated and beneficial.
Nutrition plays an important role, with attention to maintaining healthy weight to reduce stress on weakened muscles while ensuring adequate protein and calcium intake. Obesity can significantly worsen mobility issues, while undernutrition can accelerate muscle loss.
Mental health support is important, as chronic progressive conditions can impact mood and adjustment. Counseling, support groups, and peer connections through patient organizations can provide valuable emotional support and practical advice.
Educational and workplace accommodations may be needed as the condition progresses, but many individuals with BMD complete higher education and maintain successful careers. Assistive technology and adaptive equipment can help maintain independence in daily activities.
Pregnancy and fertility
BMD does not directly affect male fertility, and many men with the condition can father children. However, genetic counseling is strongly recommended to understand the inheritance pattern and options for preventing transmission to children.
Female carriers typically have normal fertility and pregnancy outcomes, though they should receive genetic counseling and may opt for prenatal testing or preimplantation genetic diagnosis. Some carrier females may develop cardiomyopathy and should receive cardiac monitoring.
Medications used to treat BMD complications should be reviewed for pregnancy safety in female partners, and cardiac status should be optimized before conception attempts.
Children
Children with BMD often have milder early symptoms than those with Duchenne muscular dystrophy, sometimes leading to delayed diagnosis. Early signs may include difficulty keeping up with peers in physical activities, enlarged calves, and elevated muscle enzymes discovered incidentally.
School accommodations may be necessary as the condition progresses, including modified physical education, assistive devices, and academic support if needed. Most children with BMD have normal cognitive development.
Regular cardiac monitoring should begin in childhood, as cardiomyopathy can develop even when skeletal muscle symptoms are mild. Maintaining physical activity as tolerated and preventing obesity are important management goals during childhood.
When to see a doctor
Urgent medical attention is needed for signs of heart problems including chest pain, severe shortness of breath, dizziness, or fainting. Sudden worsening of weakness, severe breathing difficulties, or signs of infection requiring immediate care.
Routine follow-up should include regular cardiac evaluations, pulmonary function monitoring, and assessment of functional abilities. New or worsening muscle weakness, difficulty swallowing, or sleep disturbances should prompt medical evaluation.
Family members should seek genetic counseling if BMD is diagnosed in a relative, particularly for carrier testing and family planning guidance.
Regional context
Limited specific data exists on BMD prevalence in the Caucasus region including Georgia, Armenia, and Azerbaijan. The condition likely occurs at similar rates as in other populations, but regional genetic studies would be valuable to understand local mutation patterns and founder effects.
We invite healthcare professionals and researchers from the Eastern Mediterranean and Caucasus regions to contribute data and insights about BMD prevalence and management in these populations to the Global Medical Journal.
Research and clinical trials
Research in BMD focuses on developing treatments that could slow or halt disease progression. Gene therapy approaches aim to deliver functional dystrophin genes to muscle cells, with several trials showing promising results in early phases.
Exon skipping strategies using antisense oligonucleotides attempt to restore the reading frame of dystrophin mutations, potentially converting severe Duchenne-type mutations to milder Becker-type mutations.
Utrophin upregulation therapies seek to increase production of utrophin, a protein that can partially compensate for dystrophin deficiency. Anti-inflammatory and anti-fibrotic approaches are also under investigation.
Current clinical trials can be found at ClinicalTrials.gov, and individuals with BMD may be eligible for studies testing new therapies. Participation in natural history studies and registries also contributes valuable data for future treatment development.
Frequently asked questions
Will my child with BMD lose the ability to walk?
Many individuals with BMD maintain walking ability much longer than those with Duchenne muscular dystrophy, often into their 40s or 50s. The progression varies significantly between individuals depending on their specific genetic mutation.
Can women be affected by BMD?
While rare, some female carriers can develop symptoms including muscle weakness and cardiomyopathy due to X-inactivation patterns. Most carrier females are unaffected but should receive cardiac monitoring.
Is BMD always inherited from parents?
About two-thirds of cases are inherited from carrier mothers, while one-third result from new spontaneous mutations. Family history may be negative in cases with new mutations.
How is BMD different from Duchenne muscular dystrophy?
BMD typically has later onset, slower progression, and preserved walking ability compared to Duchenne. Both conditions are caused by mutations in the same gene, but BMD mutations allow some functional dystrophin protein production.
What is the most serious complication of BMD?
Dilated cardiomyopathy affecting the heart muscle is often the most serious complication and can occur even when skeletal muscle symptoms are mild. Regular cardiac monitoring is essential for all individuals with BMD.
Support and resources
- Parent Project Muscular Dystrophy (PPMD): www.parentprojectmd.org
- Muscular Dystrophy Association: www.mda.org
- Orphanet: www.orpha.net
- EURORDIS: www.eurordis.org
- National Organization for Rare Disorders (NORD): rarediseases.org
- World Duchenne Organization: www.worldduchenne.org
Related conditions
- Duchenne muscular dystrophy
- Limb-girdle muscular dystrophy
- Dilated cardiomyopathy
- Emery-Dreifuss muscular dystrophy
- Facioscapulohumeral muscular dystrophy
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Becker muscular dystrophy.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/becker-muscular-dystrophy/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?